Supplementary Data 1 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Year: 2023
Type: supplementary-materials
Abstract: Mutation annotation file (MAF) showing all nonsynonymous exonic mutations identified in the lenvatinib/pembrolizumab cohort.
Authors: Chung-Han Lee, Renzo G. DiNatale, Diego Chowell, Chirag Krishna, Vladimir Makarov, Cristina Valero, Lynda Vuong, Mark Lee, Kate Weiss, Doug Hoen, Luc Morris, Ed Reznik, Samuel Murray, Ritesh Kotecha, Martin H. Voss, Maria I. Carlo, Darren Feldman, Pallavi Sachdev, Yusuke Adachi, Yukinori Minoshima, Junji Matsui, Yasuhiro Funahashi, Kenichi Nomoto, A. Ari Hakimi, Robert J. Motzer, Timothy A. Chan
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362484414